Race Oncology
Race Oncology is a specialty pharmaceutical company focused on rediscovering and rescuing life-saving drugs that can deliver early commercial milestones. Race Oncology’s first asset is Bisantrene, a small molecule Chemotherapy drug that has been evaluated clinically for Acute Myeloid Leukaemia (AML).
ASX Announcements
| Date | Title | |
|---|---|---|
| 25/02/2020 | Appendix 4D & Half-Year Financial Statements | Download |
| 20/02/2020 | Race significantly strengthens Clinical Advisory Board | Download |
| 17/02/2020 | Appendix 3G | Download |
| 17/02/2020 | Race appoints Australian Clinical Program Director | Download |
| 03/02/2020 | Appendix 3X-Prof Borje Andersson | Download |
| 30/01/2020 | December 2019 Quarterly Report | Download |
| 28/01/2020 | Appendix 3B | Download |
| 28/01/2020 | Clarification Announcement | Download |
| 28/01/2020 | Prof Borje Andersson appointed as Non-Executive Director | Download |
| 14/01/2020 | Notification of Expiry of Unlisted Options | Download |
ASX: RAC
Price
Latest News
Race appoints Australian Clinical Program Director
Race Oncology is pleased to welcome highly experienced oncology clinical trials specialist Dr
Race Oncology 2019 Annual General Meeting Presentation
Overview of Race Oncology's new "5 path" strategy for the development of Bisantrene.
Race appoints Dr Daniel Tillett Chief Scientific Officer
Race Oncology is pleased to announce that Dr Daniel Tillett has been appointed Chief Scientific
Professor Borje Andersson appointed Director of Race
Race Oncology Limited is pleased to announce that Professor Borje Andersson has been appointed
Prof Borje Andersson to Chair RAC Clinical Advisory Board
Race Oncology is pleased to announce that Professor Borje Andersson has agreed to chair Race’s
Don't miss important updates
Get the latest news & announcement and stay up-to-date.